메뉴 건너뛰기




Volumn 100, Issue 2, 2013, Pages 555-561

Host-targeting agents in the treatment of hepatitis C: A beginning and an end?

Author keywords

Alisporivir; Cyclophilin A; HCV; Host targeting antivirals

Indexed keywords

ALISPORIVIR; ANTIVIRUS AGENT; BC 556; CYCLOPHILIN A; CYCLOSPORIN A [4 N METHYLISOLEUCINE]; EDP 546; FATTY ACID SYNTHASE; HOST TARGETING ANTIVIRAL AGENT; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE; MICRORNA 122; MIRAVIRSEN; NVPO 18; PEGINTERFERON ALPHA; PHOSPHATIDYLINOSITOL KINASE III ALPHA; PLACEBO; RIBAVIRIN; SCAVENGER RECEPTOR BI; SCY 635; TVB 2640; UNCLASSIFIED DRUG;

EID: 84885772855     PISSN: 01663542     EISSN: 18729096     Source Type: Journal    
DOI: 10.1016/j.antiviral.2013.09.020     Document Type: Review
Times cited : (39)

References (81)
  • 2
    • 84870030071 scopus 로고    scopus 로고
    • Alisporivir (Alv) plus peg-interferon/ribavirin (Pr) in Hcv G1 treatment-experienced patients achieves primary endpoint with superior efficacy at treatment week 12 compared to retreatment with Pr
    • A. Alberti, W.L. Chuang, R. Flisiak, G. Mazzella, A. Horban, T. Goeser, P. Calistru, M. Buti, G. Davis, Y. Gong, C. Avila, and J.H. Kao Alisporivir (Alv) plus peg-interferon/ribavirin (Pr) in Hcv G1 treatment-experienced patients achieves primary endpoint with superior efficacy at treatment week 12 compared to retreatment with Pr Journal of Hepatology 56 2012 S553 S554
    • (2012) Journal of Hepatology , vol.56
    • Alberti, A.1    Chuang, W.L.2    Flisiak, R.3    Mazzella, G.4    Horban, A.5    Goeser, T.6    Calistru, P.7    Buti, M.8    Davis, G.9    Gong, Y.10    Avila, C.11    Kao, J.H.12
  • 3
    • 4644309196 scopus 로고    scopus 로고
    • The functions of animal microRNAs
    • V. Ambros The functions of animal microRNAs Nature 431 2004 350 355
    • (2004) Nature , vol.431 , pp. 350-355
    • Ambros, V.1
  • 4
    • 84867772865 scopus 로고    scopus 로고
    • Cyclophilin involvement in the replication of hepatitis C virus and other viruses
    • J. Baugh, and P. Gallay Cyclophilin involvement in the replication of hepatitis C virus and other viruses Biological Chemistry 393 2012 579 587
    • (2012) Biological Chemistry , vol.393 , pp. 579-587
    • Baugh, J.1    Gallay, P.2
  • 7
    • 0037188776 scopus 로고    scopus 로고
    • History of the discovery of cyclosporin and of its early pharmacological development
    • J.F. Borel History of the discovery of cyclosporin and of its early pharmacological development Wiener klinische Wochenschrift 114 2002 433 437
    • (2002) Wiener Klinische Wochenschrift , vol.114 , pp. 433-437
    • Borel, J.F.1
  • 14
    • 84861866572 scopus 로고    scopus 로고
    • The mechanics of miRNA-mediated gene silencing: A look under the hood of miRISC
    • M.R. Fabian, and N. Sonenberg The mechanics of miRNA-mediated gene silencing: a look under the hood of miRISC Nature Structural and Molecular Biology 19 2012 586 593
    • (2012) Nature Structural and Molecular Biology , vol.19 , pp. 586-593
    • Fabian, M.R.1    Sonenberg, N.2
  • 15
    • 78149361253 scopus 로고    scopus 로고
    • Cyclosporine inhibits a direct interaction between cyclophilins and hepatitis C NS5A
    • F. Fernandes, I.U. Ansari, and R. Striker Cyclosporine inhibits a direct interaction between cyclophilins and hepatitis C NS5A Plos One 5 2010 e9815
    • (2010) Plos One , vol.5 , pp. 9815
    • Fernandes, F.1    Ansari, I.U.2    Striker, R.3
  • 20
    • 84882886054 scopus 로고    scopus 로고
    • Isolation and characterization of interferon lambda-resistant hepatitis C virus replicon cell lines
    • J. Friborg, B. Lin, C. Chen, and F. McPhee Isolation and characterization of interferon lambda-resistant hepatitis C virus replicon cell lines Virology 444 2013 384 393
    • (2013) Virology , vol.444 , pp. 384-393
    • Friborg, J.1    Lin, B.2    Chen, C.3    McPhee, F.4
  • 21
    • 84873978406 scopus 로고    scopus 로고
    • Profile of alisporivir and its potential in the treatment of hepatitis C
    • P.A. Gallay, and K. Lin Profile of alisporivir and its potential in the treatment of hepatitis C Drug Design, Development and Therapy 7 2013 105 115
    • (2013) Drug Design, Development and Therapy , vol.7 , pp. 105-115
    • Gallay, P.A.1    Lin, K.2
  • 24
    • 65449136656 scopus 로고    scopus 로고
    • American Association for the Study of Liver, D., Diagnosis, management, and treatment of hepatitis C: An update
    • M.G. Ghany, D.B. Strader, D.L. Thomas, and L.B. Seeff American Association for the Study of Liver, D., Diagnosis, management, and treatment of hepatitis C: an update Hepatology 49 2009 1335 1374
    • (2009) Hepatology , vol.49 , pp. 1335-1374
    • Ghany, M.G.1    Strader, D.B.2    Thomas, D.L.3    Seeff, L.B.4
  • 28
    • 84867027382 scopus 로고    scopus 로고
    • All for one, one for all: New combinatorial RNAi therapies combat hepatitis C virus evolution
    • D. Grimm All for one, one for all: new combinatorial RNAi therapies combat hepatitis C virus evolution Molecular Therapy: The Journal of the American Society of Gene Therapy 20 2012 1661 1663
    • (2012) Molecular Therapy: The Journal of the American Society of Gene Therapy , vol.20 , pp. 1661-1663
    • Grimm, D.1
  • 30
    • 84879689088 scopus 로고    scopus 로고
    • 25 years of interferon-based treatment of chronic hepatitis C: An epoch coming to an end
    • M.H. Heim 25 years of interferon-based treatment of chronic hepatitis C: an epoch coming to an end Nature Reviews Immunology 13 2013 535 542
    • (2013) Nature Reviews Immunology , vol.13 , pp. 535-542
    • Heim, M.H.1
  • 31
    • 84869112137 scopus 로고    scopus 로고
    • A Unique Therapy for Hcv Inhibits Microrna-122 in Humans and Results in Hcv Rna Suppression in Chronically Infected Chimpanzees: Results from Primate and First-in-Human Studies
    • 12A-12A
    • E.S. Hildebrandt-Eriksen, Y.Z. Bagger, T.B. Knudsen, A. Petri, R. Persson, H.M. Boergesen, J.G. McHulchison, and A.A. Levin A Unique Therapy for Hcv Inhibits Microrna-122 in Humans and Results in Hcv Rna Suppression in Chronically Infected Chimpanzees: Results from Primate and First-in-Human Studies Hepatology 50 2009 12A-12A
    • (2009) Hepatology , vol.50
    • Hildebrandt-Eriksen, E.S.1    Bagger, Y.Z.2    Knudsen, T.B.3    Petri, A.4    Persson, R.5    Boergesen, H.M.6    McHulchison, J.G.7    Levin, A.A.8
  • 35
    • 84876315023 scopus 로고    scopus 로고
    • Hepatitis C Virus Replication Is Modulated by the Interaction of Nonstructural Protein NS5B and Fatty Acid Synthase
    • J.T. Huang, C.P. Tseng, M.H. Liao, S.C. Lu, W.Z. Yeh, N. Sakamoto, C.M. Chen, and J.C. Cheng Hepatitis C Virus Replication Is Modulated by the Interaction of Nonstructural Protein NS5B and Fatty Acid Synthase Journal of Virology 87 2013 4994 5004
    • (2013) Journal of Virology , vol.87 , pp. 4994-5004
    • Huang, J.T.1    Tseng, C.P.2    Liao, M.H.3    Lu, S.C.4    Yeh, W.Z.5    Sakamoto, N.6    Chen, C.M.7    Cheng, J.C.8
  • 36
    • 0038102952 scopus 로고    scopus 로고
    • Combined interferon alpha2b and cyclosporin A in the treatment of chronic hepatitis C: Controlled trial
    • K. Inoue, K. Sekiyama, M. Yamada, T. Watanabe, H. Yasuda, and M. Yoshiba Combined interferon alpha2b and cyclosporin A in the treatment of chronic hepatitis C: controlled trial Journal of Gastroenterology 38 2003 567 572
    • (2003) Journal of Gastroenterology , vol.38 , pp. 567-572
    • Inoue, K.1    Sekiyama, K.2    Yamada, M.3    Watanabe, T.4    Yasuda, H.5    Yoshiba, M.6
  • 37
    • 17844375433 scopus 로고    scopus 로고
    • Interferon combined with cyclosporine treatment as an effective countermeasure against hepatitis C virus recurrence in liver transplant patients with end-stage hepatitis C virus related disease
    • K. Inoue, and M. Yoshiba Interferon combined with cyclosporine treatment as an effective countermeasure against hepatitis C virus recurrence in liver transplant patients with end-stage hepatitis C virus related disease Transplantation Proceedings 37 2005 1233 1234
    • (2005) Transplantation Proceedings , vol.37 , pp. 1233-1234
    • Inoue, K.1    Yoshiba, M.2
  • 42
    • 24644483623 scopus 로고    scopus 로고
    • Modulation of hepatitis C virus RNA abundance by a liver-specific MicroRNA
    • C.L. Jopling, M. Yi, A.M. Lancaster, S.M. Lemon, and P. Sarnow Modulation of hepatitis C virus RNA abundance by a liver-specific MicroRNA Science 309 2005 1577 1581
    • (2005) Science , vol.309 , pp. 1577-1581
    • Jopling, C.L.1    Yi, M.2    Lancaster, A.M.3    Lemon, S.M.4    Sarnow, P.5
  • 50
    • 79951584235 scopus 로고    scopus 로고
    • Safety, pharmacokinetics, and antiviral activity of the cyclophilin inhibitor NIM811 alone or in combination with pegylated interferon in HCV-infected patients receiving 14 days of therapy
    • E. Lawitz, E. Godofsky, R. Rouzier, T. Marbury, T. Nguyen, J. Ke, M. Huang, J. Praestgaard, D. Serra, and T.G. Evans Safety, pharmacokinetics, and antiviral activity of the cyclophilin inhibitor NIM811 alone or in combination with pegylated interferon in HCV-infected patients receiving 14 days of therapy Antiviral Res. 89 3 2011 238 245
    • (2011) Antiviral Res. , vol.89 , Issue.3 , pp. 238-245
    • Lawitz, E.1    Godofsky, E.2    Rouzier, R.3    Marbury, T.4    Nguyen, T.5    Ke, J.6    Huang, M.7    Praestgaard, J.8    Serra, D.9    Evans, T.G.10
  • 54
    • 84881553622 scopus 로고    scopus 로고
    • Curing a viral infection by targeting the host: The example of cyclophilin inhibitors
    • K. Lin, and P. Gallay Curing a viral infection by targeting the host: the example of cyclophilin inhibitors Antiviral research 2013
    • (2013) Antiviral Research
    • Lin, K.1    Gallay, P.2
  • 55
    • 67449093865 scopus 로고    scopus 로고
    • Critical role of cyclophilin A and its prolyl-peptidyl isomerase activity in the structure and function of the hepatitis C virus replication complex
    • Z. Liu, F. Yang, J.M. Robotham, and H. Tang Critical role of cyclophilin A and its prolyl-peptidyl isomerase activity in the structure and function of the hepatitis C virus replication complex Journal of Virology 83 2009 6554 6565
    • (2009) Journal of Virology , vol.83 , pp. 6554-6565
    • Liu, Z.1    Yang, F.2    Robotham, J.M.3    Tang, H.4
  • 56
    • 33748687426 scopus 로고    scopus 로고
    • NIM811, a cyclophilin inhibitor, exhibits potent in vitro activity against hepatitis C virus alone or in combination with alpha interferon
    • S. Ma, J.E. Boerner, C. TiongYip, B. Weidmann, N.S. Ryder, M.P. Cooreman, and K. Lin NIM811, a cyclophilin inhibitor, exhibits potent in vitro activity against hepatitis C virus alone or in combination with alpha interferon Antimicrobial Agents and Chemotherpy 50 2006 2976 2982
    • (2006) Antimicrobial Agents and Chemotherpy , vol.50 , pp. 2976-2982
    • Ma, S.1    Boerner, J.E.2    Tiongyip, C.3    Weidmann, B.4    Ryder, N.S.5    Cooreman, M.P.6    Lin, K.7
  • 62
    • 84887478350 scopus 로고    scopus 로고
    • Cyclophilin Inhibitor EDP-546 is a Potential Cornerstone Drug for Use in Combination with NS5A and Protease Inhibitors Due to its High Barrier to HCV Resistance. Cyclophilin Inhibitor EDP-546 is a Potential Cornerstone Drug for Use in Combination with NS5A and Protease Inhibitors Due to its High Barrier to HCV Resistance
    • Amsterdam. Abstract 1213
    • Owens CM, R.M., Polemeropoulos A, Long J, Wang G, Jiang L, Or YS 2013. Cyclophilin Inhibitor EDP-546 is a Potential Cornerstone Drug for Use in Combination with NS5A and Protease Inhibitors Due to its High Barrier to HCV Resistance. Cyclophilin Inhibitor EDP-546 is a Potential Cornerstone Drug for Use in Combination with NS5A and Protease Inhibitors Due to its High Barrier to HCV Resistance, 48th Annual Meeting of the European Association for the Study of the Liver (EASL 2013), Amsterdam. Abstract 1213.
    • (2013) 48th Annual Meeting of the European Association for the Study of the Liver (EASL 2013)
    • Owens, C.M.1    Polemeropoulos, A.2    Long, J.3    Wang, G.4    Jiang, L.5    Or, Y.S.6
  • 64
    • 84880304436 scopus 로고    scopus 로고
    • Alisporivir plus Ribavirin achieves high rates of sustained HCV clearance (SVR24) as interferon (IFN)-free or IFN-add-on regimen in treatment-naive patients with HCV GT2 or GT3: Final results from VITAL-1 study
    • J.M. Pawlotsky, S.K. Sarin, G.R. Foster, C.Y. Peng, J. Rasenack, R. Flisiak, T. Piratvisuth, H. Wedemeyer, W.L. Chuang, W. Zhang, and N.V. Naoumov Alisporivir plus Ribavirin achieves high rates of sustained HCV clearance (SVR24) as interferon (IFN)-free or IFN-add-on regimen in treatment-naive patients with HCV GT2 or GT3: final results from VITAL-1 study Hepatology 56 2012 309A 310A
    • (2012) Hepatology , vol.56
    • Pawlotsky, J.M.1    Sarin, S.K.2    Foster, G.R.3    Peng, C.Y.4    Rasenack, J.5    Flisiak, R.6    Piratvisuth, T.7    Wedemeyer, H.8    Chuang, W.L.9    Zhang, W.10    Naoumov, N.V.11
  • 65
    • 84880353282 scopus 로고    scopus 로고
    • Response of hepatitis C virus to long-term passage in the presence of alpha interferon: Multiple mutations and a common phenotype
    • C. Perales, N.M. Beach, I. Gallego, M.E. Soria, J. Quer, J.I. Esteban, C. Rice, E. Domingo, and J. Sheldon Response of hepatitis C virus to long-term passage in the presence of alpha interferon: multiple mutations and a common phenotype Journal of virology 87 2013 7593 7607
    • (2013) Journal of Virology , vol.87 , pp. 7593-7607
    • Perales, C.1    Beach, N.M.2    Gallego, I.3    Soria, M.E.4    Quer, J.5    Esteban, J.I.6    Rice, C.7    Domingo, E.8    Sheldon, J.9
  • 70
    • 84880309916 scopus 로고    scopus 로고
    • Understanding the hepatitis C virus life cycle paves the way for highly effective therapies
    • T.K.H. Scheel, and C.M. Rice Understanding the hepatitis C virus life cycle paves the way for highly effective therapies Nat Med 19 2013 837 849
    • (2013) Nat Med , vol.19 , pp. 837-849
    • Scheel, T.K.H.1    Rice, C.M.2
  • 72
    • 33748455338 scopus 로고    scopus 로고
    • Type i interferons in host defense
    • D.B. Stetson, and R. Medzhitov Type I interferons in host defense Immunity 25 2006 373 381
    • (2006) Immunity , vol.25 , pp. 373-381
    • Stetson, D.B.1    Medzhitov, R.2
  • 75
    • 77951022934 scopus 로고    scopus 로고
    • The use of AlphaLISA technology to detect interaction between hepatitis C virus-encoded NS5A and cyclophilin A
    • H. Waller, U. Chatterji, P. Gallay, T. Parkinson, and P. Targett-Adams The use of AlphaLISA technology to detect interaction between hepatitis C virus-encoded NS5A and cyclophilin A J Virol Methods 165 2010 202 210
    • (2010) J Virol Methods , vol.165 , pp. 202-210
    • Waller, H.1    Chatterji, U.2    Gallay, P.3    Parkinson, T.4    Targett-Adams, P.5
  • 76
    • 0142182744 scopus 로고    scopus 로고
    • Cyclosporin A suppresses replication of hepatitis C virus genome in cultured hepatocytes
    • K. Watashi, M. Hijikata, M. Hosaka, M. Yamaji, and K. Shimotohno Cyclosporin A suppresses replication of hepatitis C virus genome in cultured hepatocytes Hepatology 38 2003 1282 1288
    • (2003) Hepatology , vol.38 , pp. 1282-1288
    • Watashi, K.1    Hijikata, M.2    Hosaka, M.3    Yamaji, M.4    Shimotohno, K.5
  • 78
    • 56149118610 scopus 로고    scopus 로고
    • Fatty acid synthase is up-regulated during hepatitis C virus infection and regulates hepatitis C virus entry and production
    • W. Yang, B.L. Hood, S.L. Chadwick, S. Liu, S.C. Watkins, G. Luo, T.P. Conrads, and T. Wang Fatty acid synthase is up-regulated during hepatitis C virus infection and regulates hepatitis C virus entry and production Hepatology 48 2008 1396 1403
    • (2008) Hepatology , vol.48 , pp. 1396-1403
    • Yang, W.1    Hood, B.L.2    Chadwick, S.L.3    Liu, S.4    Watkins, S.C.5    Luo, G.6    Conrads, T.P.7    Wang, T.8
  • 80
    • 84863012788 scopus 로고    scopus 로고
    • Evaluation of ITX 5061, a Scavenger Receptor B1 Antagonist: Resistance Selection and Activity in Combination with Other Hepatitis C Virus Antivirals
    • H.H. Zhu, F. Wong-Staal, H. Lee, A. Syder, J. McKelvy, R.T. Schooley, and D.L. Wyles Evaluation of ITX 5061, a Scavenger Receptor B1 Antagonist: Resistance Selection and Activity in Combination With Other Hepatitis C Virus Antivirals Journal of Infectious Diseases 205 2012 656 662
    • (2012) Journal of Infectious Diseases , vol.205 , pp. 656-662
    • Zhu, H.H.1    Wong-Staal, F.2    Lee, H.3    Syder, A.4    McKelvy, J.5    Schooley, R.T.6    Wyles, D.L.7
  • 81
    • 0027071803 scopus 로고
    • Active site mutants of human cyclophilin A separate peptidyl-prolyl isomerase activity from cyclosporin A binding and calcineurin inhibition
    • L.D. Zydowsky, F.A. Etzkorn, H.Y. Chang, S.B. Ferguson, L.A. Stolz, S.I. Ho, and C.T. Walsh Active site mutants of human cyclophilin A separate peptidyl-prolyl isomerase activity from cyclosporin A binding and calcineurin inhibition Protein Science 1 1992 1092 1099
    • (1992) Protein Science , vol.1 , pp. 1092-1099
    • Zydowsky, L.D.1    Etzkorn, F.A.2    Chang, H.Y.3    Ferguson, S.B.4    Stolz, L.A.5    Ho, S.I.6    Walsh, C.T.7


* 이 정보는 Elsevier사의 SCOPUS DB에서 KISTI가 분석하여 추출한 것입니다.